SCHEMBL30739059

SCHEMBL30739059

COCCc1ccc(Cn2ncc(C(=O)NCc3ccc(C(=N)N)cc3)c2COC)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 6/20 0.47
▸ F10 P00742 2/20 0.40
▸ ST14 Q9Y5Y6 2/20 0.40
▸ F2 P00734 3/20 0.39
▸ MAPK11 Q15759 2/20 0.39
▸ MAPK14 Q16539 2/20 0.39
▸ F7 P08709 1/20 0.39
▸ F3 P13726 1/20 0.39
▸ ALOX15 P16050 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP3A4 P08684 1/20 0.37
▸ GPR142 Q7Z601 1/20 0.37
▸ KLK1 P06870 1/20 0.37
▸ TPSAB1 Q15661 1/20 0.37
▸ PRSS1 P07477 1/20 0.37
▸ CYP1A1 P04798 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ PTGER4 P35408 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739113 0.88 KLKB1 (0.45) KLKB1F10F2MAPK11MAPK14
SCHEMBL30739314 0.85 KLKB1 (0.42) KLKB1F10MAPK11MAPK14L3MBTL1
SCHEMBL31591077 0.81 TSHR (0.48) KLKB1MAPK14ALOX15L3MBTL1
SCHEMBL30739057 0.80 NPC1 (0.42) L3MBTL1CYP3A4
SCHEMBL30739119 0.79 KLKB1 (0.76) KLKB1KLK1
SCHEMBL30739167 0.76 KLKB1 (0.37) KLKB1F2CYP3A4GPR142
SCHEMBL30739063 0.73 KLKB1 (0.77) KLKB1KLK1
SCHEMBL368793 0.72 NPBWR1 (0.45) ALOX15L3MBTL1PTGER4
SCHEMBL30739173 0.72 NPC1 (0.42) L3MBTL1
SCHEMBL30739045 0.71 KLKB1 (0.72) KLKB1F10KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561993-A1 INHIBITORS OF PLASMA KALLIKREIN Rezolute, Inc. (US) 2025-06-04 — — EP disclosed
WO-2024025907-A1 INHIBITORS OF PLASMA KALLIKREIN REZOLUTE, INC. (US) 2024-02-01 — — WO disclosed
Send feedback